![]() By and large, these are not needed for medical coding, but are important for tumor registries. However, they are included in the ICD-Oncology codes. Histological types such as mucinous tumors are not included in ICD-10 codes. When using CPT codes that are designated for use for ovarian malignancies, e.g., 58950 (resection of ovarian malignancy with BSO and omentectomy) a cancer code should be used. C56.9 Malignant neoplasm of unspecified ovary.C56.1 Malignant neoplasm of right ovary.D39.12 Neoplasm of uncertain behavior of left ovary. ![]() D39.11 Neoplasm of uncertain behavior of right ovary.D39.10 Neoplasm of uncertain behavior of unspecified ovary.D39.1 Neoplasm of uncertain behavior of ovary.There is therefore controversy about which code set to use. How do you code for borderline ovarian tumors or tumors of low malignant potential? Should histology types (i.e., mucinous) be included in the coding?īorderline ovarian tumors are “low malignant potential” not “no malignant potential”. For example, a stage 4 ovarian cancer may be coded using 3 codes: C56.1 (malignant neoplasm of the right ovary), C78.6 (secondary malignancy of the peritoneum and retroperitoneum, and J91.0 (malignant pleural effusion). Cancer codes for sites of metastatic disease are designated as “secondary cancer”. Yes, it is required for ICD-10 to identify the primary site of the tumor as well as sites of metastatic disease. Is it always necessary to identify the sites of advanced ovarian or fallopian tube cancer in ICD-10? The unspecified code (C56.9) might be appropriate for a patient diagnosed on biopsy if it is impossible to determine a site of origin. If you have bilateral ovarian cancer, you should use BOTH the right ovarian cancer (C56.1) and the left ovarian cancer (C56.2) codes. ICD-10 requires you to code to the greatest degree of specificity. How do you code for ovarian cancer with cancers in both ovaries? SGO expressly disclaims all responsibility and liability arising from use of, or reliance upon this information as a reference source, and assumes no responsibility or liability for any claims that may result directly or indirectly from use of this information, including, but not limited to, claims of Medicare or insurance fraud. Responses to questions are intended only as a guide and are not a substitute for specific accounting or legal opinions. However, the information neither replaces information in Medicare regulations, the CPT-4 code book, or the ICD-10 CM code book nor does it constitute legal advice. Every effort is made to ensure the accuracy of the information provided. Diversity, Inclusion, and Health Equityĭisclaimer: Answers to incoming questions are provided by the members of the Society of Gynecologic Oncology (SGO) Coding and Reimbursement subcommittee and represent their opinion based upon the current and usual practices in the field.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |